Who is sponsoring NCT05850871?

NCT05850871 is sponsored by Qianfoshan Hospital.

What drugs are being tested in NCT05850871?

Interventions in NCT05850871: CAZ/AVI plus Aztreonam, Conventional treatment.

What condition does NCT05850871 study?

NCT05850871 studies Carbapenem-Resistant Enterobacteriaceae Infection.

Is NCT05850871 still recruiting?

NCT05850871 is currently status unknown. Last updated 9 May 2023.

Last reviewed 2023-05-09 · How we verify

NCT05850871

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies

Status unknown NA Last updated 9 May 2023

What this trial tests

NA trial testing CAZ/AVI plus Aztreonam in Carbapenem-Resistant Enterobacteriaceae Infection in 427 participants. Status unknown.

Timeline

6 January 2023

Primary endpoint
31 January 2025

31 January 2025

Quick facts

Lead sponsor	Qianfoshan Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	single
Primary purpose	treatment
Enrollment	427
Start date	6 January 2023
Primary completion	31 January 2025
Estimated completion	31 January 2025
Sites	1 location across China

Drugs / interventions tested

CAZ/AVI plus Aztreonam — full drug profile →
Conventional treatment — full drug profile →

Conditions studied

Carbapenem-Resistant Enterobacteriaceae Infection — all drugs for Carbapenem-Resistant Enterobacteriaceae Infection →

Sponsor

Qianfoshan Hospital

Who can join

Eligibility, any sex, with Carbapenem-Resistant Enterobacteriaceae Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The first aim of this study is to explore the drug resistance mechanism of Enterobacteriaceae bacteria and to evaluate the treatment effect of ceftazidime-avibactam (CAZ-AVI) in combination with aztreonam (ATM) against Metallo-β-lactamases (MBL) producing Enterobacterales in vivo. The investigators then use CRISPR/Cas9 technology to remove Enterobacteriaceae bacteria resistance and virulence genes

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Cell-Penetrating Peptides and CRISPR-Cas9: A Combined Strategy for Human Genetic Disease Therapy.
de Morais CCPL, Correia EM, Bonamino MH, Vasconcelos ZFM. · · 2024 · cited 6× · PMID 39276086 · DOI 10.1089/hum.2024.020
Therapeutic applications of CRISPR-Cas9 gene editing.
Bharti A, Mudge J. · · 2025 · PMID 41476860 · DOI 10.3389/fgeed.2025.1724291

Verify or expand the search:

Other recruiting trials for Carbapenem-Resistant Enterobacteriaceae Infection

Currently open trials in the same condition.

NCT05979545 — EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics · Phase 4 · recruiting
NCT06051513 — Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae I · NA · recruiting
NCT07086391 — Different Methods of Aerosolized Polymyxin B Inhalation for Treating Carbapenem-Resistant Gram-Negative Bacterial Pneumo · recruiting
NCT05871476 — Interventions to Decrease CRE Colonization and Transmission Between Hospitals, Households, Communities and Domesticated · NA · recruiting
NCT04535661 — Risk Factors for Colonization or Infection With Carbapenem-Resistant Enterobacteriaceae in Children · recruiting

Other Qianfoshan Hospital trials

Trials by the same sponsor.

NCT05727618 — The Effect of Pituitrin on the Patients With Pulmonary Hypertension Undergoing Cardiac Surgery · NA · suspended
NCT06837831 — Mepilex Lite Dressings for the Treatment of Acute Radiation Dermatitis of Anal Canal Skin · NA · recruiting
NCT07260760 — Clinical Comprehensive Evaluation of Neuroprotective Drugs for Acute Ischemic Stroke · not yet recruiting
NCT07362667 — A Study of the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With ABPA · recruiting
NCT07271849 — Nalbuphine Timing Effects on Hemodynamics and Analgesia in Elderly Patients · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05850871 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Qianfoshan Hospital
Last refreshed: 9 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05850871.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing